| Literature DB >> 35519104 |
Eman Shawky1, Ahmed A Nada1, Reham S Ibrahim1.
Abstract
Since the outbreak of Coronavirus disease (COVID-19) caused by SARS-CoV-2 in December 2019, there has been no vaccine or specific antiviral medication for treatment of the infection where supportive care and prevention of complications is the current management strategy. In this work, the potential use of medicinal plants and more than 16 500 of their constituents was investigated within two suggested therapeutic strategies in the fight against SARS-CoV-2 including prevention of SARS-CoV-2 RNA synthesis and replication, through targeting vital proteins and enzymes as well as modulation of the host's immunity through production of virulence factors. Molecular docking studies on the viral enzymes 3Clpro, PLpro and RdRp suggested rocymosin B, verbascoside, rutin, caftaric acid, luteolin 7-rutinoside, fenugreekine and cyanidin 3-(6''-malonylglucoside) as promising molecules for further drug development. Meanwhile, the medicinal plants Glycyrrhiza glabra, Hibiscus sabdariffa, Cichorium intybus, Chrysanthemum coronarium, Nigella sativa, Anastatica hierochuntica, Euphorbia species, Psidium guajava and Epilobium hirsutum were enriched in compounds with the multi-targets PTGS2, IL2, IL1b, VCAM1 and TNF such as quercetin, ursolic acid, kaempferol, isorhamnetin, luteolin, glycerrhizin and apigenin. Enriched pathways of the molecular targets included cytokine-cytokine receptor interaction, TNF signaling pathway, NOD-like receptor signaling pathway, Toll-like receptor signaling pathway, NF-kappa B signaling pathway and JAK-STAT3 signaling pathway which are all closely related to inflammatory, innate and adaptive immune responses. The present study identified natural compounds targeting SARS-CoV-2 for further in vitro and in vivo studies and emphasizes the potential role of medicinal plants in the mitigation of SARS-CoV-2. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35519104 PMCID: PMC9055652 DOI: 10.1039/d0ra05126h
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Docking scores of the top 20 hits identified in addition to lopinavir, nelfinavir and remedesivir against the three viral proteins studied
| 3CLpro | PLpro | RdRp | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Compound | Docking score | Plant source | Compound | Docking score | Plant source | Compound | Docking score | Plant source | |
| 1 |
| −12.632 |
|
| −14.041 |
|
| −11.541 |
|
| 2 |
| −11.844 |
|
| −13.883 |
|
| −10.664 |
|
| 3 |
| −11.721 |
|
| −11.148 |
|
| −9.894 |
|
| 4 |
| −11.624 |
|
| −10.832 |
|
| −9.797 |
|
| 5 |
| −11.412 |
|
| −10.674 |
|
| −9.785 |
|
| 6 |
| −11.409 |
|
| −10.658 |
|
| −9.754 |
|
| 7 |
| −11.363 |
|
| −10.593 |
|
| −9.747 |
|
| 8 |
| −11.119 |
|
| −10.504 |
|
| −9.732 |
|
| 9 |
| −11.061 |
|
| −10.49 |
|
| −9.611 |
|
| 10 |
| −11.015 |
|
| −10.402 |
|
| −9.544 |
|
| 11 |
| −11.015 |
|
| −10.338 |
|
| −9.527 |
|
| 12 |
| −10.892 |
|
| −10.255 |
|
| −9.509 |
|
| 13 |
| −10.88 |
|
| −10.201 |
|
| −9.493 |
|
| 14 |
| −10.831 |
|
| −10.182 |
|
| −9.485 |
|
| 15 |
| −10.811 |
|
| −10.18 |
|
| −9.484 |
|
| 16 |
| −10.762 |
|
| −10.162 |
|
| −9.403 |
|
| 17 |
| −10.695 |
|
| −10.041 |
|
| −9.361 |
|
| 18 |
| −10.684 |
|
| −10.035 |
|
| −9.31 |
|
| 19 |
| −10.658 |
|
| −10.027 |
|
| −9.298 |
|
| 20 |
| −10.624 |
|
| −10.027 |
|
| −9.278 |
|
|
| −10.195 | Lopinavir | −8.625 | Lopinavir | −5.94 | ||||
|
| −8.297 | Nelfinavir | −4.324 | Nelfinavir | −7.594 | ||||
|
| −7.346 | Remdesivir | −3.947 | Remdesivir | −8.526 | ||||
Fig. 13D (to the left) and 2D (to the right) interaction diagrams of (A) rutin, (B) rocymosin b and (C) verbascoside with the crystal structure of 3CLpro (PDB ID: 5R7Y).
Fig. 23D (to the left) and 2D (to the right) interaction diagrams of (A) verbascoside, (B) luteolin-7-rutinoside and (C) caftaric acid with the crystal structure of PLpro (PDB ID: 6W9C).
Fig. 33D (to the left) and 2D (to the right) interaction diagrams of (A) cyanidin 3-(6′′-malonylglucoside), (B) caftaric acid and (C) fenugreekine with the crystal structure of RdRp (PDB ID: 6M71).
Fig. 4Compound–viral target network colored according to number of common neighbors. Multi-target nodes are colored orange. Node size is proportional to the relative docking score of the compound in the network.
Fig. 5Plant-viral target network colored according to number of common neighbors. Nodes are colored according to their topological coefficients; nodes with three targets are colored green and nodes with two targets are colored blue. Node size is proportional to the relative total docking scores of the compounds in the plants included the network.
Identified potential protein targets of the different compounds in medicinal plants and the involved pathways
| Protein | Interacting compound (s) | Involved pathways |
|---|---|---|
| AKT1 | Isorhamnetin, salidroside, apigenin, myricetin, genistein | VEGF signaling pathway, Toll-like receptor signaling pathway, B cell receptor signaling pathway, TNF signaling pathway, tuberculosis, influenza A |
| NOS2 | Isorhamnetin | Pertussis, tuberculosis |
| MAPK8 | Luteolin, quercetagetin, isorhamnetin | Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, TNF signaling pathway, pertussis, tuberculosis |
| PTGS2 | Catechin, eupafolin, withaferin A, apigenin, medicocarpin, | NF-kappa B signaling pathway, VEGF signaling pathway, TNF signaling pathway, prostaglandin-endoperoxide synthase activity |
| ALOX5 | Protocatechuic acid, kaempferol, quercetin | Arachidonic acid metabolism |
| CASP3 | Alternariol, apigenin, kaempferol, salidroside, gallic acid, isoquercitrin, myricetin, chrysin, hispolon | TNF signaling pathway, pertussis, tuberculosis |
| CASP8 | Aloe-emodin | NOD-like receptor signaling pathway |
| CASP9 | Aloe-emodin, alternariol | VEGF signaling pathway, tuberculosis, influenza A |
| FOS | Luteolin | Toll-like receptor signaling pathway, T cell receptor signaling pathway, B cell receptor signaling pathway, TNF signaling pathway, pertussis |
| HSP90AA1 | Aloe-emodin | NOD-like receptor signaling pathway |
| IL1B | Quercetin, ursolic acid, isorhmnetin, | Cytokine–cytokine receptor interaction, NF-kappa B signaling pathway, TNF signaling pathway, MAPK signaling pathway, IL-17 signaling pathway, Th17 cell differentiation, pertussis, influenza A, tuberculosis |
| IL2 | Quercetin, ursolic acid | T cell receptor signaling pathway, Th17 cell differentiation, cytokine–cytokine receptor interaction |
| IL10 | Salidroside | FoxO signaling pathway |
| STAT1 | Acacetin, quercetin | Cytokine–cytokine receptor interaction |
| JUN | Acacetin, gallic acid, kaempferol, luteolin | Toll-like receptor signaling pathway, T cell receptor signaling pathway, B cell receptor signaling pathway, TNF signaling pathway |
| KDR | 1-Methoxyphaseollidin, astragalin, gancaonin B, glycyrin, licochalcone G | Cytokine–cytokine receptor interaction, VEGF signaling pathway, MAPK signaling pathway, ras signaling pathway |
| PTGS2 | Astragalin, calycosin, glyzaglabrin, isoliquiritigenin, isorhamnetin, kaempferol, naringenin, quercetin, ursolic acid | Arachidonic acid metabolism |
| TNF | Glycyrrhizin, kaempferol, naringin, quercetin, ursolic acid | Cytokine–cytokine receptor interaction, NF-kappa B signaling pathway, TNF signaling pathway, MAPK signaling pathway, IL-17 signaling pathway, HTLV-I infection, pertussis, human papillomavirus infection, T cell receptor signaling pathway, influenza A, tuberculosis |
| SMAD2 | Luteolin | FoxO signaling pathway |
| VCAM1 | Isoliquiritigenin, kaempferol, quercetin | NF-kappa B signaling pathway, TNF signaling pathway |
| VEGFA | Acacetin, hispidulin, quercetin, ursolic acid | NF-kappa B signaling pathway, VEGF signaling pathway, MAPK signaling pathway, human papillomavirus infection, PI3K-Akt signaling pathway |
| PIK3CG | Myricetin | TNF signaling pathway |
| NOS3 | Genistein kaempferol, luteolin, luteolin-7- | VEGF signaling pathway, HIF-1 signaling pathway |
| GADPH | Koningic acid | HIF-1 signaling pathway |
| MMP9 | Luteolin, gallic acid, hispolon | TNF signaling pathway |
Fig. 6(A) Compounds-target–pathway network. The orange circles represent the identified compounds, the green circles represent potential targets in inflammation and immunity. (B) Protein–protein interaction (PPI) network of identified targets colored according to degree of interaction.
Fig. 7(A) Analysis of the top 10 scoring plants merged plant-compound–target–pathway network. (B) The distributions % of the C–T interactions on the compounds identified. (C) The distributions % of the C–T interactions on the top 10 scoring medicinal plants in the database.
KEGG pathway analysis of the identified pathways in the network
| # term ID | Term description | Observed gene count | False discovery rate | Matching proteins in network |
|---|---|---|---|---|
| hsa04668 | TNF signaling pathway | 11 | 1.30 × 10−17 | AKT1, CASP3, CASP8, FOS, IL1B, JUN, MAPK8, MMP9, PTGS2, TNF, VCAM1 |
| hsa04657 | IL-17 signaling pathway | 10 | 2.27 × 10−16 | CASP3, CASP8, FOS, HSP90AA1, IL1B, JUN, MAPK8, MMP9, PTGS2, TNF |
| hsa05161 | Hepatitis B | 10 | 1.08 × 10−14 | AKT1, CASP3, CASP8, CASP9, FOS, JUN, MAPK8, MMP9, STAT1, TNF |
| hsa05152 | Tuberculosis | 10 | 6.08 × 10−14 | AKT1, CASP3, CASP8, CASP9, IL10, IL1B, MAPK8, NOS2, STAT1, TNF |
| hsa04010 | MAPK signaling pathway | 9 | 2.33 × 10−10 | AKT1, CASP3, FOS, IL1B, JUN, KDR, MAPK8, TNF, VEGFA |
| hsa05133 | Pertussis | 8 | 3.76 × 10−13 | CASP3, FOS, IL10, IL1B, JUN, MAPK8, NOS2, TNF |
| hsa04620 | Toll-like receptor signaling pathway | 8 | 3.94 × 10−12 | AKT1, CASP8, FOS, IL1B, JUN, MAPK8, STAT1, TNF |
| hsa04659 | Th17 cell differentiation | 8 | 3.94 × 10−12 | FOS, HSP90AA1, IL1B, IL2, JUN, MAPK8, SMAD2, STAT1 |
| hsa04210 | Apoptosis | 8 | 2.75 × 10−11 | AKT1, CASP3, CASP8, CASP9, FOS, JUN, MAPK8, TNF |
| hsa05168 | Herpes simplex infection | 8 | 2.33 × 10−10 | CASP3, CASP8, FOS, IL1B, JUN, MAPK8, STAT1, TNF |
| hsa05166 | HTLV-I infection | 8 | 2.31 × 10−9 | AKT1, FOS, IL2, JUN, MAPK8, SMAD2, TNF, VCAM1 |
| hsa04151 | PI3K-Akt signaling pathway | 8 | 2.24 × 10−8 | AKT1, CASP9, HSP90AA1, IL2, KDR, NOS3, PIK3CG, VEGFA |
| hsa05321 | Inflammatory bowel disease (IBD) | 7 | 1.14 × 10−11 | IL10, IL1B, IL2, JUN, SMAD2, STAT1, TNF |
| hsa04621 | NOD-like receptor signaling pathway | 7 | 4.91 × 10−9 | CASP8, HSP90AA1, IL1B, JUN, MAPK8, STAT1, TNF |
| hsa05164 | Influenza A | 7 | 5.12 × 10−9 | AKT1, CASP9, IL1B, JUN, MAPK8, STAT1, TNF |
| hsa05165 | Human papillomavirus infection | 7 | 2.72 × 10−7 | AKT1, CASP3, CASP8, PTGS2, STAT1, TNF, VEGFA |
| hsa04370 | VEGF signaling pathway | 6 | 7.66 × 10−10 | AKT1, CASP9, KDR, NOS3, PTGS2, VEGFA |
| hsa04660 | T cell receptor signaling pathway | 6 | 1.09 × 10−8 | AKT1, FOS, IL10, IL2, JUN, TNF |
| hsa04060 | Cytokine–cytokine receptor interaction | 6 | 1.85 × 10−6 | IL10, IL1B, IL2, KDR, TNF, VEGFA |
| hsa04658 | Th1 and Th2 cell differentiation | 5 | 2.91 × 10−7 | FOS, IL2, JUN, MAPK8, STAT1 |
| hsa05144 | Jak-STAT signaling pathway | 4 | 1.28 × 10−6 | AKT1, IL10, IL2, STAT1 |
| hsa04064 | NF-kappa B signaling pathway | 4 | 1.41 × 10−5 | IL1B, PTGS2, TNF, VCAM1 |
| hsa04066 | HIF-1 signaling pathway | 4 | 1.66 × 10−5 | AKT1, NOS2, NOS3, VEGFA |
| hsa04068 | FoxO signaling pathway | 4 | 4.41 × 10−5 | AKT1, IL10, MAPK8, SMAD2 |
| hsa05160 | Hepatitis C | 4 | 4.41 × 10−5 | AKT1, MAPK8, STAT1, TNF |
| hsa04630 | Malaria | 4 | 8.87 × 10−5 | IL10, IL1B, TNF, VCAM1 |
| hsa05169 | Epstein–Barr virus infection | 4 | 0.00018 | AKT1, IL10, JUN, MAPK8 |
| hsa04014 | Ras signaling pathway | 4 | 0.00029 | AKT1, KDR, MAPK8, VEGFA |
| hsa04662 | B cell receptor signaling pathway | 3 | 0.00018 | AKT1, FOS, JUN |
| hsa04920 | Adipocytokine signaling pathway | 3 | 0.00018 | AKT1, MAPK8, TNF |
| hsa01521 | EGFR tyrosine kinase inhibitor resistance | 3 | 0.00024 | AKT1, KDR, VEGFA |
| hsa04611 | Platelet activation | 3 | 0.00078 | AKT1, NOS3, PIK3CG |
| hsa05310 | Asthma | 2 | 0.001 | IL10, TNF |
| hsa04672 | Intestinal immune network for IgA production | 2 | 0.0022 | IL10, IL2 |
| hsa00590 | Arachidonic acid metabolism | 2 | 0.0038 | ALOX5, PTGS2 |
| hsa04750 | Inflammatory mediator regulation of TRP channels | 2 | 0.0078 | IL1B, MAPK8 |
| hsa05322 | Systemic lupus erythematosus | 2 | 0.0081 | IL10, TNF |
| hsa04670 | Leukocyte transendothelial migration | 2 | 0.0111 | MMP9, VCAM1 |
| hsa04062 | Chemokine signaling pathway | 2 | 0.0236 | AKT1, STAT1 |
Fig. 8(A) GO enrichment analysis identified targets. Biological processes are colored orange, cellular components are blue and molecular functions are green. (B) BBID (blue), BIOCARTA (green), INTERPRO (grey) and KEGG (orange) pathways analysis involved in inflammation and immunity. The order of importance was ranked by −log10(P-value) with bar chart. The number of target stick into each term with line chart.